ClinicalTrials.Veeva

Menu

PENG Block vs. ESP Block for Pediatric Hip Surgery

P

Poznan University of Medical Sciences (PUMS)

Status and phase

Completed
Phase 4

Conditions

Hip Injuries
Hip Fractures
Hip Disease
Hip Dysplasia

Treatments

Drug: Erector Spinae Plane Block using 0.2% ropivacaine
Drug: Pericapsular nerve group block using 0.2% ropivacaine
Other: Standard care

Study type

Interventional

Funder types

Other

Identifiers

Details and patient eligibility

About

The study compares the effectiveness and safety of the pericapsular nerve blockade vs. ESPB in pediatric patients who underwent hip surgeries.

Full description

The study compares the effectiveness and safety of the pericapsular nerve blockade vs. ESPB in pediatric patients who underwent hip surgeries. In addition, we aim to determine the optimal volume of local anesthetics needed to achieve a satisfactory level of analgesia.

Enrollment

90 patients

Sex

All

Ages

2 months to 12 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • pediatric patients aged between 0-12 years who will undergo hip surgery

Exclusion criteria

  • a history of chronic pain use of gabapentin/pregabalin for > 3 months opioid use > 1 repeated opioid prescription in the last three months
  • morbid obesity (BMI > 99th percentile)
  • Infection at block application area
  • coagulopathy

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Triple Blind

90 participants in 3 patient groups

Control group
Active Comparator group
Description:
regional anesthesia: spinal anesthesia - 0,1ml/kg 0,5% ropivacaine
Treatment:
Other: Standard care
Pericapsular nerve group block (PENG) group
Active Comparator group
Description:
regional anesthesia: spinal anesthesia - 0,1ml/kg 0,5% ropivacaine + PENG block - 0.5mL/kg 0.2% ropivacaine, max. 20mL
Treatment:
Drug: Pericapsular nerve group block using 0.2% ropivacaine
Erector Spinae Plane Block (ESPB) group
Active Comparator group
Description:
regional anesthesia: spinal anesthesia - 0,1ml/kg 0,5% ropivacaine + ESP block - 0.5mL/kg 0.2% ropivacaine, max. 20mL
Treatment:
Drug: Erector Spinae Plane Block using 0.2% ropivacaine

Trial contacts and locations

1

Loading...

Central trial contact

Malgorzata Domagalska, Ph.D.

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems